Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Clinical trial NCT03744468 · COMPLETED

Trial details

NCT number: NCT03744468
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in HNSCC for Phase 2 Dose Expansion NSCLC for Phase 2 Dose Expansion

Start date: 2018-11-13
Primary completion: 2025-02-06
Enrollment: 147

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.